Sign up for blue cross blue shield - tennessee Policy ID_CHS_60512026a_0926 alerts
Get alerted when Policy ID_CHS_60512026a_0926 changes without checking for updates manually.
Monitor payer policy activity
Receive email alerts as soon as relevant payer policies are published or updated.
This policy establishes prior authorization and medical necessity criteria for leuprolide acetate depot suspension for pediatric central precocious puberty and gender-affirming care, including clinical, documentation, and prescriber requirements.
No material clinical or coverage changes in this revision.
2Covered indication categories
12 monthsInitial authorization period
Tanner 2+Puberty threshold for gender-affirming suppression
Not coveredOther indications
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.
12 months
Continued gender-transition authorization
Covered and Noncovered Indications
Initial Therapy: Central Precocious Puberty
Authorization of 12 months may be granted for treatment of central precocious puberty (CPP) when <strong>all</strong> of the following criteria are met:
ALL of the following
ONE of the following diagnostic criteria
A pubertal response to a gonadotropin-releasing hormone (GnRH) agonist test, based on the laboratory reference range.
A pubertal basal level of luteinizing hormone (LH) on a third-generation LH assay, based on the laboratory reference range.
ONE of the following member criteria
The assessment of bone age versus chronological age supports the diagnosis of CPP.
The member is female and was less than 8 years of age at the onset of secondary sexual characteristics.
The member is male and was less than 9 years of age at the onset of secondary sexual characteristics.
The pathologic cause of CPP has been assessed, such as imaging screening for intracranial tumors or genetic testing for familial CPP (e.g., MKRN3 or DLK1 variants).
Authorization of 12 months may be granted for pubertal hormonal suppression in an adolescent member seeking gender-affirming care when <strong>all</strong> of the following criteria are met. The individual must be age 18 or older, or less than age 18 as permissive under applicable law.
ALL of the following
The member is able to make an informed decision to engage in treatment.
The member has a diagnosis of gender dysphoria.
The member has reached Tanner stage 2 of puberty or greater.
The member has been educated on any contraindications and side effects to therapy.
The member's comorbid conditions are reasonably controlled.
Initial Therapy: Gender Transition
Authorization of 12 months may be granted for gender transition in a member seeking gender-affirming care when <strong>all</strong> of the following criteria are met. The individual must be age 18 or older, or less than age 18 as permissive under applicable law.
ALL of the following
The member is able to make an informed decision to engage in treatment.
The member has a diagnosis of gender dysphoria.
The member will receive the requested medication concomitantly with gender-affirming hormones.
The member has been educated on any contraindications and side effects to therapy.
The member's comorbid conditions are reasonably controlled.
Continuation Therapy: Central Precocious Puberty
Authorization of up to 12 months may be granted for continued treatment of CPP when <strong>both</strong> of the following criteria are met:
ALL of the following
The member is not experiencing treatment failure, such as clinical pubertal progression, lack of growth deceleration, or continued excessive bone age advancement.
Authorization of 12 months may be granted for continued treatment for pubertal hormonal suppression in an adolescent member seeking gender-affirming care and requesting reauthorization when <strong>all</strong> of the following criteria are met. The individual must be age 18 or older, or less than age 18 as permissive under applicable law.
ALL of the following
The member is able to make an informed decision to engage in treatment.
The member has a diagnosis of gender dysphoria.
The member has previously reached Tanner stage 2 of puberty or greater.
The member's comorbid conditions are reasonably controlled.
The member has been educated on any contraindications and side effects to therapy.
Continuation Therapy: Gender Transition
Authorization of 12 months may be granted for continued treatment for gender transition in a member seeking gender-affirming care and requesting reauthorization when <strong>all</strong> of the following criteria are met. The individual must be age 18 or older, or less than age 18 as permissive under applicable law.
ALL of the following
The member is able to make an informed decision to engage in treatment.
The member has a diagnosis of gender dysphoria.
The member will receive the requested medication concomitantly with gender-affirming hormones.
The member has been educated on any contraindications and side effects to therapy.
The member's comorbid conditions are reasonably controlled.
Gender dysphoria, also known as transgender and gender diverse (TGD) persons, is a compendial use. All other indications are considered experimental/investigational and not medically necessary.
Leuprolide acetate depot suspension is not medically necessary for indications other than listed FDA-approved or compendial uses.
Initial Authorization Requirements
Central Precocious Puberty: Initial 12-Month Authorization
Authorization of 12 months may be granted for treatment of central precocious puberty when all of the following criteria are met.
CPP initial therapy
Diagnostic confirmation
A pubertal response to a gonadotropin-releasing hormone agonist test is documented.
A pubertal basal luteinizing hormone level on a third-generation assay is documented.
Supporting CPP criterion
Assessment of bone age versus chronological age supports the diagnosis of central precocious puberty.
Age at onset
Continued Authorization Requirements
Central Precocious Puberty: Continued Treatment
Authorization of up to 12 months may be granted for continued treatment of central precocious puberty when both criteria are met.
CPP continuation: The member is not experiencing treatment failure and is either a female less than 12 years of age or a male less than 13 years of age.Female <12 years; male <13 years
Treatment failure includes clinical pubertal progression, lack of growth deceleration, or continued excessive bone age advancement.
Gender Dysphoria: Continued Gender-Affirming Treatment
Authorization of 12 months may be granted for continued gender-affirming treatment when all of the following criteria are met.
Gender-affirming continuation: For pubertal suppression, the member must be able to make an informed decision, have gender dysphoria, have previously reached Tanner stage 2 or greater, have reasonably controlled comorbid conditions, have received education about contraindications and side effects, and have been informed of fertility preservation options before therapy. For gender transition, the member must also receive the medication concomitantly with gender-affirming hormones.
Authorization, Documentation, and Denial Risks
Prior Authorization
Prior Authorization and Clinical Evidence
Prior authorization is required for covered use of leuprolide acetate depot suspension. The request must include the applicable clinical evidence for the requested indication, including the documentation required for initial central precocious puberty (CPP) review.
Covered indications are subject to all applicable approval criteria and member benefit exclusions.
For initial CPP requests, submit documentation of a pubertal response to a GnRH agonist test or a pubertal basal LH level on a third-generation LH assay.
Prior Authorization
12-Month Continuation Authorization
Reauthorization may be granted for 12 months for continued pubertal hormonal suppression or gender-transition treatment when all applicable continuation criteria are met.
For continued pubertal hormonal suppression, the member must be able to make an informed treatment decision, have gender dysphoria, have previously reached Tanner stage 2 or greater, and have reasonably controlled comorbid conditions.
Therapy and Policy Context
Lupron Depot-PED is leuprolide acetate depot therapy used for pediatric central precocious puberty. The policy also recognizes gender dysphoria, including transgender and gender-diverse persons, as a compendial use for pubertal hormonal suppression or gender transition when the applicable clinical, counseling, and prescribing requirements are met.
Clinical Definitions
Central precocious puberty (CPP)
DefinitionEarly activation of puberty, or central precocious puberty (CPP).
Diagnostic confirmationConfirm CPP using laboratory reference ranges with either a pubertal response to a gonadotropin-releasing hormone (GnRH) agonist test or a pubertal basal luteinizing hormone (LH) level on a third-generation LH assay.
Supporting evidenceEither bone-age assessment compared with chronological age supports the diagnosis, or the age-at-onset criterion is met: female younger than 8 years or male younger than 9 years at onset of secondary sexual characteristics.
Etiologic assessmentThe pathologic cause of CPP must be assessed, including evaluation such as imaging for intracranial tumors or genetic testing for familial CPP when applicable.
The member has been informed of fertility preservation options.
The member has been informed of fertility preservation options.
Before the start of therapy, the member has been informed of fertility preservation options.
Before the start of therapy, the member has been informed of fertility preservation options.
The member was female and less than 8 years of age at onset of secondary sexual characteristics.<8 years
The member was male and less than 9 years of age at onset of secondary sexual characteristics.<9 years
The pathologic cause of central precocious puberty has been assessed, such as through imaging screening for intracranial tumors or genetic testing for familial central precocious puberty, including MKRN3 or DLK1 variants.
Authorization of 12 months may be granted for pubertal hormonal suppression in an adolescent member seeking gender-affirming care when all of the following criteria are met.
Gender-affirming pubertal suppression: The member is able to make an informed decision to engage in treatment; has a diagnosis of gender dysphoria; has reached Tanner stage 2 or greater; has received education about contraindications and side effects; has reasonably controlled comorbid conditions; and has been informed of fertility preservation options.Tanner stage 2 or greater
The individual must be age 18 or older or younger than 18 as permissive under applicable law.
Gender Transition: Initial Authorization
Authorization of 12 months may be granted for gender transition in a member seeking gender-affirming care when all of the following criteria are met.
Gender transition: The member is able to make an informed decision to engage in treatment; has a diagnosis of gender dysphoria; will receive the requested medication concomitantly with gender-affirming hormones; has received education about contraindications and side effects; has reasonably controlled comorbid conditions; and has been informed of fertility preservation options.Concomitant gender-affirming hormones
The individual must be age 18 or older or younger than 18 as permissive under applicable law.
Tanner stage 2+; concomitant gender-affirming hormones for transition
The individual must be age 18 or older or younger than 18 as permissive under applicable law.
Authorization of 12 months may be granted for continued treatment for gender transition when all of the following criteria are met.
12-month continuation authorization: The member is able to make an informed decision to engage in treatment; has a diagnosis of gender dysphoria; will receive the requested medication concomitantly with gender-affirming hormones; has been educated on contraindications and side effects; has reasonably controlled comorbid conditions; and, before the start of therapy, was informed of fertility preservation options.
For continued gender-transition treatment, the member must be able to make an informed treatment decision, have gender dysphoria, receive the medication concomitantly with gender-affirming hormones, and have reasonably controlled comorbid conditions.
For either continuation indication, required education regarding contraindications and side effects must be documented; fertility-preservation counseling must have occurred before therapy began.
Documentation Required
CPP Diagnostic Documentation
For an initial CPP request, submit a laboratory report or medical-record documentation confirming a pubertal response to a GnRH agonist test or a pubertal basal LH level on a third-generation LH assay.
The CPP diagnosis must be confirmed using the applicable laboratory reference range.
Documentation Required
Gender Dysphoria Provider Documentation
For gender dysphoria, leuprolide must be prescribed by or in consultation with a provider specialized in the care of transgender youth. For members younger than 18, the provider must have collaborated care with a mental health provider.
Examples of specialized providers include a pediatric endocrinologist, family or internal medicine physician, or obstetrician-gynecologist.
Document the specialty provider involvement and, when applicable, collaboration with a mental health provider.
Documentation Required
Continuation Treatment Documentation
Continuation requests must document the member's ongoing eligibility and treatment requirements for the applicable indication. The record must support informed decision-making, the diagnosis of gender dysphoria, appropriate medication use, and required counseling and safety assessments.
Document that the member is able to make an informed decision to engage in treatment and continues to have a diagnosis of gender dysphoria.
For continued pubertal hormonal suppression, document that the member previously reached Tanner stage 2 or greater.
For continued gender transition, document concomitant use of gender-affirming hormones.
Document education on contraindications and side effects and that comorbid conditions are reasonably controlled.
Document that fertility-preservation options were discussed before the start of therapy.
Unsupported block type: denial_risk
Denial Risk
CPP Criteria Not Met
A CPP request may be denied when the diagnosis is not confirmed or when required clinical evidence is missing.
The request must document either a pubertal response to a GnRH agonist test or a pubertal basal LH level on a third-generation LH assay, based on the applicable laboratory reference range.
The request must support the CPP diagnosis through bone-age assessment relative to chronological age and applicable age-of-onset criteria: female members younger than 8 at onset of secondary sexual characteristics or male members younger than 9 at onset.
The pathologic cause of CPP must be assessed, such as through imaging screening for intracranial tumors or genetic testing for familial CPP, including MKRN3 or DLK1 variants.
Denial Risk
Gender-Affirming Criteria Not Met
A gender-affirming treatment request may be denied when any required clinical criterion is not met for the requested initial or continuation therapy.
The member must be able to make an informed decision to engage in treatment and have a diagnosis of gender dysphoria.
For initial pubertal hormonal suppression, the member must have reached Tanner stage 2 or greater; for continuation, the member must have previously reached Tanner stage 2 or greater.
For gender transition, the requested medication must be used concomitantly with gender-affirming hormones.
The member must be educated on contraindications and side effects, have reasonably controlled comorbid conditions, and be informed of fertility-preservation options before therapy begins.
Documentation Required
Prescriber Specialty Requirement
The medication must be prescribed by or in consultation with a provider specialized in transgender youth care. Missing specialty involvement or required mental-health collaboration can prevent authorization.
Acceptable examples include a pediatric endocrinologist, family or internal medicine physician, or obstetrician-gynecologist with expertise in transgender youth care.
For members younger than 18, the specialized provider must have collaborated care with a mental health provider.
Denial Risk
Failure to Meet Continuation Criteria
Failure to satisfy any applicable continuation criterion creates a risk of denial for reauthorization. The continuation request must support the member's current clinical status and ongoing treatment plan.
Denial risk includes inability to make an informed treatment decision, no documented diagnosis of gender dysphoria, or failure to meet the applicable Tanner-stage requirement.
For gender-transition reauthorization, denial risk includes lack of concomitant gender-affirming hormones.
Denial risk also includes uncontrolled comorbid conditions, missing education regarding contraindications or side effects, or missing documentation that fertility-preservation options were discussed before therapy began.
Note
State Age Restrictions
State regulatory guidelines concerning gender dysphoria may impose age restrictions. Confirm that the member's age and treatment are permissible under applicable Tennessee law before submitting or renewing authorization.
The policy states that an individual must be age 18 or older, or younger than 18 as permissive under applicable law, for the listed gender-affirming authorization criteria.
Gender dysphoria, also described as transgender and gender diverse (TGD) persons, is a compendial indication recognized by the policy.
Compendial useLeuprolide may be used for pubertal hormonal suppression or gender transition in a member seeking gender-affirming care when the policy criteria are met.
Pubertal suppression thresholdFor pubertal hormonal suppression, the member must have reached Tanner stage 2 of puberty or greater.
Gender-transition requirementFor gender transition, the requested medication must be received concomitantly with gender-affirming hormones.
Additional requirementsThe member must be able to make an informed decision, have reasonably controlled comorbid conditions, receive education about contraindications and side effects, and be informed of fertility-preservation options.